Shin Nippon Biomedical Laboratories (SNBL)
Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.
15 contract research organizations in our directory list both Safety Pharmacology and Rat among their capabilities, across 8 countries. 15 report GLP capability and 5 report AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.
Showing 15 CROs. Order rotates daily so no lab is permanently listed first.
Long-established Japanese CRO with large GLP nonclinical safety facilities and deep nonhuman primate experience, supporting toxicology, safety pharmacology and pharmacokinetics.
Beijing-based preclinical CRO focused on GLP safety evaluation, with branches across China and support for biologics, nucleic acid and cell and gene therapies.
Specialty preclinical CRO focused on hearing research, offering ototoxicity, otoprotection and auditory efficacy studies.
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
Japanese preclinical CRO offering GLP safety and efficacy studies for drugs, devices and regenerative products, with long minipig experience.
Independent German preclinical CRO conducting GLP toxicology, reproductive toxicology, carcinogenicity and safety pharmacology studies across rodent and non-rodent species.
Non-clinical CRO near Milan and part of the NMS Group, offering GLP safety assessment and toxicology, safety pharmacology and preclinical regulatory consulting to move candidates toward IND/CTA.
Large China-based nonclinical CRO offering GLP safety assessment, pharmacology, pharmacokinetics and bioanalysis, with operations in China and the United States.
South Korea's first private non-clinical CRO, providing GLP toxicity, safety pharmacology, pharmacokinetic and efficacy studies for drugs, chemicals and biologics.
French CRO combining early clinical development with preclinical pharmacology, offering CNS and cardiovascular safety pharmacology and translational neuroscience models.
Preclinical CRO with GLP laboratories near Budapest and offices in Munich, offering safety assessment, ADME-PK, bioanalysis and pharmacodynamic models.
Shanghai-based nonclinical CRO with GLP safety evaluation, pharmacology, DMPK, bioanalysis and biomarker services for small molecules, biologics and cell and gene therapies, operating several sites in China.
Specialty CRO focused on cardiovascular safety pharmacology and cardiovascular toxicology, including telemetry and hemodynamic studies in non-rodent species.